A trailing price-to-earnings ratio of 120 sits next to a price-to-sales ratio near its highest point in a decade. Those two numbers describe the same stock on the same day, and they tell opposite stories about what investors think they are buying.
The P/E, a ratio that compares the stock price to the profit earned per share, looks alarming because one-time acquisition charges have temporarily crushed reported earnings. The P/S, which compares the stock price to raw sales, looks alarming for a different reason: the market is paying more for each dollar of Merck’s revenue than it has at almost any point in the past ten years. One number says the stock is distorted by accounting noise. The other says the mood, meaning what investors are currently willing to pay, has run well ahead of the math, meaning what the filed fundamentals actually justify. That gap is the story.
The heart of it
Merck’s underlying business is genuinely strong: revenue grew to $65 billion in fiscal 2025, margins are near decade highs, and a string of FDA approvals in 2026 has expanded the product lineup beyond its flagship cancer drug. The stock has gained substantially over the past twelve months, and our data shows the price-to-sales ratio is now at the 99th percentile of Merck’s own decade-long range, meaning the market is paying a premium it has almost never paid before. The open question is whether a pipeline that management says could reach $70 billion in commercial opportunity by the mid-2030s is worth that premium, given that the drug generating nearly half of today’s pharmaceutical revenue loses its core U.S. patent protection in late 2028.
What the conversation is saying
Merck’s stock has become a battleground between two very loud camps, and the argument turns almost entirely on one drug: Keytruda, the immunotherapy that has become the best-selling cancer medicine in the world.
The bull case, articulated by JPMorgan when it revised its valuation outlook in August 2026, rests on momentum. Keytruda keeps finding new uses, new combination therapies keep winning FDA approval, and the pipeline behind it is filling in. Merck CEO Rob Davis said in February 2026 that the company has “line of sight to over $70 billion of potential commercial opportunity by the mid-2030s” from its pipeline. New drugs like Winrevair, for a rare lung condition called pulmonary arterial hypertension, and Welireg, for kidney cancer, are growing fast enough to be noticed.
The bear case is simpler and harder to dismiss. Bears, pointing to valuation and execution risk, note that the consensus analyst valuation estimate sits below the current stock price. Keytruda’s core U.S. patents expire in late 2028, threatening a revenue stream that accounted for roughly $29.5 billion in 2024 sales, or nearly half of Merck’s pharmaceutical revenue that year. When a single product generates close to half your income and its legal protection ends in two years, the math demands a very convincing answer about what replaces it.
Testing the claims against the filings
The 10-K for fiscal year 2025 shows a business that is, by most measures, performing well. Full-year revenue reached $65 billion, and free cash flow, the actual cash left after running the business and investing in its future, came in at a level more than enough to fund acquisitions, dividends, and buybacks simultaneously. The net margin is near the top of the decade range, confirming the core business is efficient.
The 10-Q for the quarter ended June 30, 2026 adds texture. Worldwide sales grew modestly from a year earlier. Keytruda and its newer subcutaneous version, Keytruda QLEX, together produced $8.4 billion in that single quarter. Winrevair and Welireg each posted growth rates above sixty percent. Those growth rates are impressive, but the base is still small: the two newer drugs together generated roughly a tenth of what Keytruda did in the same quarter.
The GAAP loss per share for Q2 2026 is real but explained. A large charge tied to the acquisition of Terns Pharmaceuticals drove it. Think of it like a household that took out a loan to buy a rental property: the upfront cost hits the budget hard in year one, but the underlying income from the rest of the household’s work did not disappear. The non-GAAP gross margin of 81.1% in Q2 2026 confirms the core business is still extracting more than 80 cents of gross profit from every dollar of sales.
One figure in the filings deserves a pause. R&D spending in 2025 reached $15.8 billion, roughly a quarter of total revenue. A household earning a good salary and spending a quarter of it on education and retraining is either building something durable or burning through savings on a gamble. Which one it is depends on whether the courses pay off.
The approvals are real, and so is the clock
Between January and September 2026, Merck collected a notable string of FDA approvals. The agency cleared a new HIV drug called IDVYNSO in April, an oral cholesterol drug called LIPFENDRA in July (the first of its class taken as a pill rather than injected), and multiple new uses for Keytruda in bladder and kidney cancers. The pipeline page on Merck’s website lists candidates across oncology, cardiovascular disease, infectious disease, and vaccines.
These approvals matter because they represent revenue that does not depend on Keytruda’s patent. LIPFENDRA, as the first oral PCSK9 inhibitor, a class of drugs that lowers bad cholesterol, enters a market that has been dominated by injectable versions that many patients find inconvenient. A pill version of the same therapy could reach patients who never bothered with the injections. That is a real commercial opportunity, not a projection.
But the Keytruda clock is also real. Generic competition for the diabetes drugs Januvia and Janumet began in mid-2026, creating a meaningful revenue headwind. That is a preview of what happens at scale when Keytruda’s protection ends. Merck’s management acknowledged on the August 4, 2026 earnings call that U.S. Keytruda growth will moderate as the drug approaches peak penetration in several key cancer indications.
Where the math and the mood diverge
Our data shows Merck’s adjusted P/E sits just above its decade median, which sounds reasonable. But that figure uses the non-GAAP earnings that strip out acquisition charges. The trailing GAAP P/E, which uses the earnings actually reported to shareholders, sits at 120. The P/S ratio is at the 99th percentile of Merck’s own decade range, meaning the market has almost never paid this much for a dollar of Merck’s revenue.
The consensus analyst valuation estimate, as reported by Rockflow, sits below the current stock price, meaning the stock has already priced in a great deal of the good news. Management’s own raised guidance for 2026 calls for revenue growth roughly in line with the broader economy. That is not the growth rate that typically commands a price-to-sales ratio at a decade high.
If the pipeline delivers and Keytruda’s successors fill the revenue gap before 2028, the current premium may look prescient. If execution stumbles or the patent cliff arrives before the replacements are ready, the math at today’s price leaves little cushion. Those two outcomes are genuinely uncertain, and the filed numbers cannot resolve them.
Reading the numbers
- $65.0 billion, FY2025 revenue (10-K, fiscal year 2025): Merck’s total sales for the year. What it means: the business is large and stable, growing about 1% from 2024’s $64.2 billion. Everyday version: a company that sells $65 billion a year is roughly the size of the entire economy of a mid-sized country. Growth at 1% means it is holding its ground, not sprinting.
- 28.1%, net margin, FY2025 (10-K, fiscal year 2025): the share of each dollar of sales that became profit after every bill was paid. What it means: near the top of Merck’s decade range, confirming the core business is efficient. Everyday version: of every $100 a customer pays for a Merck medicine, about $28 ends up as profit. Most manufacturers keep closer to $5 to $10.
- P/S at the 99th percentile of the decade range (our data): the price-to-sales ratio compares the stock’s market value to annual revenue. At the 99th percentile of its own history, investors are paying more per dollar of Merck’s sales than they have in virtually any prior year. Everyday version: imagine a bakery that has always sold for roughly four times its annual bread sales. Today someone is offering to buy it for nearly six times. Either they know something about future bread sales, or they are paying too much.
- $15.8 billion, R&D spending, FY2025 (Q4 2025 earnings presentation): money spent on discovering and testing new drugs. What it means: roughly one dollar in four of revenue goes back into the research engine. Everyday version: a firm earning $65 billion and spending $15.8 billion on research is betting heavily that the next generation of drugs justifies today’s price. If those bets pay off, the spending looks like investment. If they don’t, it looks like cost.
- $8.4 billion, Keytruda family sales, Q2 2026 (10-Q, quarter ended June 30, 2026): one quarter of sales from one drug family. What it means: annualized, that is roughly $33 billion from a single franchise whose core U.S. patent expires in late 2028. Everyday version: imagine a restaurant where one menu item accounts for nearly half of all orders. It is a wonderful item. But the recipe becomes public in two years.
For the standing yardsticks on Merck & Co: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Merck & Co.
Sources
- Merck 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Merck 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Merck Q2 2026 financial results
- Merck Q2 2026 earnings call transcript, August 4, 2026
- Merck Q4 2025 earnings presentation
- Merck pipeline and regulatory milestones
- Zacks: MRK Q2 earnings, raised 2026 guidance
- Rockflow: MRK analyst ratings and valuation estimates
- Investing.com: Merck pipeline analysis, 2026
- StocksToTrade: JPMorgan valuation outlook revision, August 2026
- GuruFocus: Merck trailing P/E
